Lixte Biotechnology Holdings Stock Piotroski F Score

LIXT Stock  USD 3.52  1.26  55.75%   
This module uses fundamental data of Lixte Biotechnology to approximate its Piotroski F score. Lixte Biotechnology F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Lixte Biotechnology Holdings. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Lixte Biotechnology financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Lixte Biotechnology Altman Z Score, Lixte Biotechnology Correlation, Lixte Biotechnology Valuation, as well as analyze Lixte Biotechnology Alpha and Beta and Lixte Biotechnology Hype Analysis.
  
Cash Flow To Debt Ratio is likely to gain to 14.36 in 2024, despite the fact that Net Debt is likely to grow to (4 M). At this time, Lixte Biotechnology's Interest Coverage is comparatively stable compared to the past year. Quick Ratio is likely to gain to 14.06 in 2024, whereas Dividend Payout Ratio is likely to drop (0.0009) in 2024.
At this time, it appears that Lixte Biotechnology's Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

No Change

Focus

Lixte Biotechnology Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Lixte Biotechnology is to make sure Lixte is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Lixte Biotechnology's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Lixte Biotechnology's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.260.3
Fairly Down
Slightly volatile
Total Current Liabilities290.7 K313.9 K
Significantly Down
Slightly volatile
Total Assets2.2 M4.3 M
Way Down
Slightly volatile
Total Current Assets2.2 M4.2 M
Way Down
Slightly volatile

Lixte Biotechnology F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Lixte Biotechnology's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Lixte Biotechnology in a much-optimized way.

About Lixte Biotechnology Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Price Book Value Ratio

1.18

At this time, Lixte Biotechnology's Price Book Value Ratio is comparatively stable compared to the past year.

About Lixte Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lixte Biotechnology is a strong investment it is important to analyze Lixte Biotechnology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lixte Biotechnology's future performance. For an informed investment choice regarding Lixte Stock, refer to the following important reports:

Complementary Tools for Lixte Stock analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.66)
Return On Assets
(0.64)
Return On Equity
(1.11)
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.